AcroBiosystems社 Treatment of Cancer Improved by Combination Therapy Regimen
Treatment of Cancer Improved by Combination Therapy Regimen
The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC). Besides, A new preclinical study suggests that combining immune checkpoint inhibitors targeting PD-1/ PD-L1 with MAPK-targeted therapy—drugs typically used separately— may help overcome cancer treatment resistance.
More and more studies have shown that immune checkpoint combination therapy has a good effect in dealing with cancer.
ACROBiosystems has developed an exclusive immune checkpoint protein collection.
Immunization and antibody screening
Wonder how can these immune checkpoint proteins help your drug development?
The protocols are available for free!
Flow Cytometry assay shows that Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) can bind to 293 cells overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。